


U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE		DATE: June 23, 2005
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. Application No. (if known): 10/540485
INTERNATIONAL APPLICATION NO.: PCT/JP2003/009845	INTERNATIONAL FILING DATE: August 1, 2003	PRIORITY DATE CLAIMED: December 26, 2002
TITLE OF INVENTION: ALKYNYL-SUBSTITUTED AZASUGAR DERIVATIVE AND DRUG CONTAINING THE SAME AS THE ACTIVE INGREDIENT		
APPLICANT(S) FOR DO/EO/US: Takahiro TSUKIDA et al.		
Applicant hereby submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 USC 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input checked="" type="checkbox"/> The US has been elected (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)): <ol style="list-style-type: none"> a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US) 6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 		
ITEMS 11. TO 20. BELOW CONCERN OTHER DOCUMENT(S) OR INFORMATION INCLUDED:		
<ol style="list-style-type: none"> 11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98 together with the international search report, PTO/SB/08 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. ASSIGNEE NAME AND ADDRESS: CARNA BIOSCIENCES, INC., Tokyo, Japan Please publish the assignee data with the application. 13. <input type="checkbox"/> A preliminary amendment. 14. <input type="checkbox"/> An Application Data Sheet under 37 C.F.R. 1.76 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 C.F.R. 1.821 - 1.825. 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input type="checkbox"/> Other items or information: 		

U.S. APPLICATION NO. (if known) 10/540485		INTERNATIONAL APPLICATION NO. PCT/JP2003/009845		DATE: June 23, 2005	
21. <u>XX</u> The following fees are submitted: Basic National Stage Fee National Stage Search Fee National Stage Examination Fee ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS \$ 300.00 \$ 500.00 \$ 200.00 \$ 1,000.00	PTO USE ONLY
Surcharge of \$130.00 for furnishing the oath or declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).					
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
TOTAL	4 -20 =		X \$ 50.00		
INDEPENDENT	2 - 3 =		X \$ 200.00		
Multiple dependent claims(s) (if applicable)			+ \$360.00		
TOTAL OF ABOVE CALCULATIONS =				\$ 1,000.00	
National Stage Application Size Fee-for each additional 50 sheets that exceeds 100 sheets \$ 250.00.					
Reduction by 1/2 for filing by small entity, if applicable. (Note 37 CFR 1.9, 1.27, 1.28).					
SUBTOTAL =				\$ 1,000.00	
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)). +					
TOTAL NATIONAL FEE =				\$ 1,000.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +					
TOTAL FEES ENCLOSED =				\$ 1,000.00	
				Amount to be:	
				refunded	\$
				charged	\$
a. <u>XX</u> A check in the amount of <u>\$1,000.00</u> to cover the above fees is enclosed. (\$300.00 for basic national stage fee; \$500.00 for national stage search fee; \$200.00 for national stage examination fee). b. Please charge my Deposit Account No. 50-2866 in the amount of \$ to cover the above fees. (A duplicate copy of this sheet is enclosed.) c. <u>XX</u> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-2866. NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed to request that the application be restored to pending status.					
Send All Correspondence To:			WESTERMAN, HATTORI, DANIELS & ADRIAN, LLP 1250 Connecticut Avenue, N.W. Suite 700 Washington, D.C. 20036 CUSTOMER No. 38834		
Typed or Printed Name: Sadao Kinashi			Reg. No.: 48,075		
Signature 			Date: June 23, 2005		

SK/yap